• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于优化稳定性和溶解性的新型抗结核药物组合离子液体形式

New Ionic Liquid Forms of Antituberculosis Drug Combinations for Optimized Stability and Dissolution.

作者信息

Rasmy Hanan E, Abouelmagd Sara A, Ibrahim Elsayed A

机构信息

Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt.

Institute for Drug Development and Innovation Research, Assiut University, Assiut, Egypt.

出版信息

AAPS PharmSciTech. 2025 Jan 8;26(1):27. doi: 10.1208/s12249-024-03023-1.

DOI:10.1208/s12249-024-03023-1
PMID:39779636
Abstract

Isoniazid (INH) and rifampicin (RIF) are the two main drugs used for the management of tuberculosis. They are often used as a fixed drug combination, but their delivery is challenged by suboptimal solubility and physical instability. This study explores the potential of active pharmaceutical ingredient-ionic liquids (API-ILs) to improve the physicochemical and pharmaceutical properties of INH and RIF. Antitubercular drugs, INH, or RIF, were paired with different counter ions (ascorbic acid (AsA), citric acid (CA), tartaric acid (TA), benzoic acid (BA), salicylic acid (SA), and p-amino salicylic acid (PAS)) using the solvent evaporation method. INH and RIF API-ILs were formed successfully using AsA and CA counter ions. IL formation was examined and analyzed using Fourier transform infrared (FTIR) spectroscopy, x-ray powder diffraction (XRPD), and polarized optical microscopy (POM). XRPD and POM confirmed their amorphous nature, while FTIR analysis demonstrated the contribution of hydrogen bonding to IL formation. IL formation enhanced the storage stability of the INH + RIF mixture in the presence of CA. Moreover, RIF-CA IL significantly increased the rate and extent of RIF dissolution. An effect that is unattainable with the RIF/CA physical mixture. Thus, API-IL formation not only enhances RIF dissolution but also facilitates the preparation of stable, compatible INH-RIF combinations.

摘要

异烟肼(INH)和利福平(RIF)是用于治疗结核病的两种主要药物。它们常以固定药物组合的形式使用,但其给药受到溶解度欠佳和物理稳定性的挑战。本研究探讨了活性药物成分 - 离子液体(API - ILs)改善INH和RIF的物理化学及药学性质的潜力。采用溶剂蒸发法将抗结核药物INH或RIF与不同的抗衡离子(抗坏血酸(AsA)、柠檬酸(CA)、酒石酸(TA)、苯甲酸(BA)、水杨酸(SA)和对氨基水杨酸(PAS))配对。使用AsA和CA抗衡离子成功形成了INH和RIF的API - ILs。使用傅里叶变换红外(FTIR)光谱、X射线粉末衍射(XRPD)和偏光显微镜(POM)对离子液体的形成进行了检测和分析。XRPD和POM证实了它们的非晶态性质,而FTIR分析表明氢键对离子液体形成的贡献。在CA存在的情况下,离子液体的形成增强了INH + RIF混合物的储存稳定性。此外,RIF - CA离子液体显著提高了RIF的溶解速率和程度。这是RIF/CA物理混合物无法实现的效果。因此,API - IL的形成不仅增强了RIF的溶解,还促进了稳定、相容的INH - RIF组合的制备。

相似文献

1
New Ionic Liquid Forms of Antituberculosis Drug Combinations for Optimized Stability and Dissolution.用于优化稳定性和溶解性的新型抗结核药物组合离子液体形式
AAPS PharmSciTech. 2025 Jan 8;26(1):27. doi: 10.1208/s12249-024-03023-1.
2
Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid.在异烟肼存在的情况下,抗坏血酸可提高利福平的稳定性和药代动力学。
J Pharm Biomed Anal. 2014 Nov;100:103-108. doi: 10.1016/j.jpba.2014.07.027. Epub 2014 Aug 1.
3
Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.使用异烟肼-咖啡酸和香草酸共晶提高抗结核固定剂量组合药物的稳定性。
J Pharm Sci. 2018 Jun;107(6):1667-1679. doi: 10.1016/j.xphs.2018.02.014. Epub 2018 Feb 17.
4
Stability of rifampicin in dissolution medium in presence of isoniazid.利福平在异烟肼存在下于溶出介质中的稳定性。
Int J Pharm. 1999 Nov 10;190(1):109-23. doi: 10.1016/s0378-5173(99)00286-0.
5
Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.利福平与异烟肼复方肠溶片的设计与评价。
Pharm Dev Technol. 2013 Mar-Apr;18(2):401-6. doi: 10.3109/10837450.2012.659254. Epub 2012 Feb 18.
6
A mesoporous silicon/poly-(DL-lactic-co-glycolic) acid microsphere for long time anti-tuberculosis drug delivery.介孔硅/聚(DL-乳酸-共-乙醇酸)微球用于长时间抗结核药物递送。
Int J Pharm. 2014 Dec 10;476(1-2):116-23. doi: 10.1016/j.ijpharm.2014.09.040. Epub 2014 Sep 28.
7
Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH.将利福平包封在固体脂质纳米粒系统中以限制其在酸性 pH 下的降解和与异烟肼的相互作用。
Int J Pharm. 2013 Mar 25;446(1-2):106-11. doi: 10.1016/j.ijpharm.2013.02.012. Epub 2013 Feb 11.
8
Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy.异烟肼和利福平共包封于脂质体中及脂质体的导数光谱表征
Int J Pharm. 2004 Mar 1;271(1-2):115-23. doi: 10.1016/j.ijpharm.2003.10.033.
9
Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug-Polymer Immiscibility to Enable Processing for Solid Dosage Forms.喷雾包封作为基于药物的室温离子液体的配方策略:利用药物-聚合物不混溶性来实现固体剂型的加工。
Mol Pharm. 2020 Sep 8;17(9):3412-3424. doi: 10.1021/acs.molpharmaceut.0c00467. Epub 2020 Aug 27.
10
Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs.妥尔油脂肪酸聚氧乙烯醚(Tyloxapol)非离子脂质体的配方,用于包裹、稳定和溶解抗结核药物。
Colloids Surf B Biointerfaces. 2013 Jan 1;101:434-41. doi: 10.1016/j.colsurfb.2012.07.006. Epub 2012 Jul 17.

本文引用的文献

1
Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features.固体口服药物治疗中的固定剂量复方制剂:优势、局限性及设计特点
Pharmaceutics. 2024 Jan 26;16(2):178. doi: 10.3390/pharmaceutics16020178.
2
Enhanced Physical Stability of L-Ascorbic Acid in an Ionic Liquid.在离子液体中增强抗坏血酸的物理稳定性。
Chem Pharm Bull (Tokyo). 2024 Feb 21;72(2):209-212. doi: 10.1248/cpb.c23-00861. Epub 2024 Jan 26.
3
Citric Acid: Properties, Microbial Production, and Applications in Industries.
柠檬酸:性质、微生物生产及在工业中的应用。
Molecules. 2023 Dec 19;29(1):22. doi: 10.3390/molecules29010022.
4
Ionic Liquids: New Forms of Active Pharmaceutical Ingredients with Unique, Tunable Properties.离子液体:具有独特可调性质的新型活性药物成分。
Chem Rev. 2023 Oct 25;123(20):11894-11953. doi: 10.1021/acs.chemrev.3c00384. Epub 2023 Oct 5.
5
Therapeutic deep eutectic solvents: A comprehensive review of their thermodynamics, microstructure and drug delivery applications.治疗性深共晶溶剂:它们的热力学、微观结构和药物传递应用的综合评述。
Eur J Pharm Biopharm. 2023 May;186:85-104. doi: 10.1016/j.ejpb.2023.03.002. Epub 2023 Mar 11.
6
Role and Recent Advancements of Ionic Liquids in Drug Delivery Systems.离子液体在药物递送系统中的作用及最新进展
Pharmaceutics. 2023 Feb 20;15(2):702. doi: 10.3390/pharmaceutics15020702.
7
WHO's Global Tuberculosis Report 2022.世界卫生组织《2022年全球结核病报告》。
Lancet Microbe. 2023 Jan;4(1):e20. doi: 10.1016/S2666-5247(22)00359-7. Epub 2022 Dec 12.
8
Active pharmaceutical ingredients (APIs) in ionic liquids: An effective approach for API physiochemical parameter optimization.离子液体中的活性药物成分(APIs):优化 API 物理化学参数的有效方法。
Drug Discov Today. 2022 Sep;27(9):2415-2424. doi: 10.1016/j.drudis.2022.06.003. Epub 2022 Jun 11.
9
Prediction of H NMR chemical shifts for ionic liquids: strategy and application of a relative reference standard.离子液体的¹H NMR化学位移预测:相对参考标准的策略与应用
RSC Adv. 2018 Aug 10;8(50):28604-28612. doi: 10.1039/c8ra04822c. eCollection 2018 Aug 7.
10
API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility.离子液体活性成分:探究抗衡离子结构对物理形态和脂质溶解度的影响。
RSC Adv. 2020 Mar 31;10(22):12788-12799. doi: 10.1039/d0ra00386g. eCollection 2020 Mar 30.